

EXECUTIVE SUMMARY

2025-Q2



- 1,829.2 mn Eur, PPP*, 11.1% Sales Growth
- 172.2 mn units, 1.1% Volume Growth
- 2,709.3 mn DOT, 3.2% DOT Growth

YTD (2025-Q2)


- 3,687.7 mn Eur, PPP*, 12.3% Sales Growth
- 357.7 mn units, 2.1% Volume Growth
- 5,556.1 mn DOT, 4.0% DOT Growth

MAT (2025-Q2)


- 7,258.1 mn Eur, PPP*, 12.7% Sales Growth
- 717.3 mn units, 0.8% Volume Growth
- 11,050.8 mn DOT, 2.5% DOT Growth




MARKET SPLIT BY CHANNEL AND STATUS - MAT (2025-Q2), PPP, EUR




MARKET GROWTH BY CHANNEL AND STATUS - PPP, EUR



EXECUTIVE SUMMARY



- ASTRAZENECA
- SUN PHARMA1
- ZENTIVA2
- JOHNSON & JOHNSON
- SERVIER3
- PFIZER
- SANOFI
- HOFFMANN LA ROCHE
- NOVARTIS
- MERCK & CO
- NOVO NORDISK
- VIATRIS
- ELI LILLY
- BAYER AG
- ABBVIE
- MENARINI
- BRISTOL MYERS SQUIBB
- SANDOZ
- GLAXOSMITHKLINE
- RECKITT BENCKISER
- All others



¹ including Terapia
² including Alvogen and Labomed
³ including Egis

TOP 20 BRANDS

Crt. No.	Top 20 brands PRODUCT NAME	Values PPP 2025 - Q2 EUR, mn	Values PPP 2025 - Q2 +/- %	Values PPP YTD(2025 - Q2) EUR, mn	Values PPP YTD(2025 - Q2) +/- %	Values PPP MAT(2025 - Q2) EUR, mn	Values PPP MAT(2025 - Q2) +/- %
	Total market	1,829.2	11.1%	3,687.7	12.3%	7,258.1	12.7%
	Top 20 Rx and OTC drugs	257.2	16.4%	504.6	17.6%	989.6	20.8%
1	NUROFEN	20.8	2.7%	46.2	5.4%	94.0	8.5%
2	RYBELSUS	22.6	50.8%	43.2	63.7%	80.6	74.1%
3	DARZALEX	20.4	19.2%	38.9	18.9%	77.3	25.8%
4	IMBRUVICA	18.3	2.1%	36.4	1.9%	72.5	2.2%
5	FORXIGA	16.5	28.8%	31.6	29.7%	60.3	35.9%
6	TAGRISSO	15.2	5.7%	29.4	6.3%	58.8	14.0%
7	ASPENTER	13.1	30.2%	25.1	25.1%	46.2	17.0%
8	VESSEL DUE F	10.9	12.4%	21.6	13.8%	44.4	17.7%
9	IBRANCE	11.1	1.7%	21.2	-1.4%	43.5	2.2%
10	DETRELEX	11.0	7.1%	21.5	8.6%	43.3	7.0%
11	XIGDUO	10.9	19.1%	21.4	19.1%	41.6	21.7%
12	VERZENIOS	10.7	22.7%	21.0	30.2%	40.7	46.7%
13	PHESGO	8.9	-16.2%	17.3	-13.4%	37.9	2.1%
14	VENCLYXTO	9.0	8.2%	18.3	13.8%	36.4	17.7%
15	CLEXANE	9.0	-25.1%	18.3	-16.0%	36.2	-9.3%
16	HEPCLUDEX	12.3	>1000%	22.2	>1000%	35.9	>1000%
17	TRULICITY	9.0	-6.7%	17.4	-10.5%	35.8	-8.8%
18	TRESIBA	9.0	1.7%	17.6	2.5%	35.5	6.9%
19	SORTIS	9.4	15.4%	18.4	9.4%	34.9	5.7%
20	JARDIANCE	9.1	28.6%	17.7	38.5%	33.8	53.3%
	CVR drugs	13.8	30.9%	31.6	25.3%	76.9	-0.2%
	CV drugs	272.8	24.1%	533.8	26.5%	1,010.0	28.0%

TOP 20 CORPORATIONS

Crt. No.	CORPORATION	Values PPP 2025 - Q2 EUR, mn	Values PPP 2025 - Q2 +/- %	Values PPP YTD(2025 - Q2) EUR, mn	Values PPP YTD(2025 - Q2) +/- %	Values PPP MAT(2025 - Q2) EUR, mn	Values PPP MAT(2025 - Q2) +/- %
	Total	1,829.2	11.1%	3,687.7	12.3%	7,258.1	12.7%
1	ASTRAZENECA	102.0	9.4%	200.1	19.9%	387.3	24.4%
2	SUN PHARMA ¹	81.5	11.1%	166.4	12.1%	325.4	9.4%
3	ZENTIVA ²	74.5	2.4%	152.1	5.0%	304.4	7.6%
4	JOHNSON & JOHNSON	68.0	8.6%	133.8	9.1%	265.1	11.4%
5	SERVIER ³	63.9	5.5%	127.1	6.5%	254.0	7.9%
6	PFIZER	61.2	5.6%	119.9	5.4%	239.3	7.0%
7	SANOFI	54.4	2.0%	107.7	4.4%	220.1	4.3%
8	HOFFMANN LA ROCHE	53.0	6.2%	109.4	12.6%	216.1	18.6%
9	NOVARTIS	56.2	11.6%	110.2	13.1%	215.4	15.2%
10	MERCK & CO	55.9	23.1%	106.3	22.9%	206.5	29.3%
11	NOVO NORDISK	49.6	-0.4%	96.5	1.1%	192.0	6.3%
12	VIATRIS	41.8	3.3%	84.7	3.3%	171.8	3.1%
13	ELI LILLY	46.4	33.1%	84.4	26.7%	157.5	23.9%
14	BAYER AG	34.2	-3.0%	67.9	-2.5%	136.9	-0.9%
15	ABBVIE	31.9	8.7%	65.2	16.1%	133.5	12.1%
16	MENARINI	33.5	14.0%	66.4	13.4%	130.0	9.6%
17	BRISTOL MYERS SQUIBB	31.7	8.7%	63.6	14.1%	125.5	17.6%
18	SANDOZ	28.6	-1.2%	60.4	3.9%	120.2	8.5%
19	GLAXOSMITHKLINE	29.6	6.9%	58.7	7.5%	116.6	7.7%
20	RECKITT BENCKISER	24.7	2.3%	56.1	5.9%	114.4	10.3%
	All others	806.8	13.8%	1,650.9	15.1%	3,226.1	14.0%